Abstract
The objectives of this study were to: (a) estimate the costs of providing a single-session HIV prevention intervention and a multi-session intervention, and (b) estimate the number of HIV transmissions that would need to be prevented for the intervention to be cost-saving or cost-effective (threshold analysis). Project START was evaluated with 522 young men aged 18–29 years released from eight prisons located in California, Mississippi, Rhode Island, and Wisconsin. Cost data were collected prospectively. Costs per participant were $689 for the single-session comparison intervention, and ranged from $1,823 to 1,836 for the Project START multi-session intervention. From the incremental threshold analysis, the multi-session intervention would be cost-effective if it prevented one HIV transmission for every 753 participants compared to the single-session intervention. Costs are comparable with other HIV prevention programs. Program managers can use these data to gauge costs of initiating these HIV prevention programs in correctional facilities.
Resumen
Los objetivos de este estudio fueron: (a) estimar los costos de proveer una intervención de prevención del VIH en una sola sesión y una intervención en sesiones múltiples; y (b) estimar el número de transmisiones de VIH que habría que evitar para que la intervención ahorre costos o sea costo-efectiva (análisis de umbral). El proyecto START se evaluó con 522 hombres jóvenes de 18 a 29 años liberados de ocho prisiones de California, Mississippi, Rhode Island y Wisconsin. Los datos de costos se recogieron de forma prospectiva. Los costos por participante fueron de $689 para la intervención de comparación en una sola sesión, y osciló entre $1823 a $1836 para la intervención del proyecto multi-sesión START. A partir del análisis de umbral incremental, la intervención en sesiones múltiples sería costo-efectiva si se impide una transmisión del VIH por cada 753 participantes en comparación con la intervención en una sola sesión. Los costos son comparables con otros programas de prevención del VIH. Directores de programas pueden usar estos datos para determinar los costos de iniciar estos programas de prevención del VIH en centros penitenciarios.
Similar content being viewed by others
References
West H, Minton T, Simmons S, Snell T. Prisoners at year end 2009—advance counts. Washington DC: US Department of Justice Officer of Justice Programs; 2010.
Maruschak L, Beavers R. HIV in prisons, 2007–2008. Washington DC: US Department of Justice Office of Justice Programs; 2009.
Hogben M, St. Lawrence J, Eldridge GD. Sexual risk behavior, drug use, and STD rates among incarcerated women. Women Health. 2001;34:63–78.
Morris RE, Harrison EA, Knox GW, Tromnhauser E, Marquis DK, Watts LL. Health risk behavioral survey from 39 juvenile correctional facilities in the United States. J Adolesc Health. 1995;17:334–344.
Margolis AD, MacGowan RJ, Grinstead O, et al. Unprotected sex with multiple partners: implications for HIV prevention among young men with a history of incarceration. Sex Transm Dis. 2006;33(3):175–80.
Morris RE, Baker CJ, Valentine M, Pennisi AJ. Variations in HIV risk behaviors of incarcerated juveniles during a four-year period: 189–1992. J Adolesc Health. 1998;23:39–48.
Teplin LA, Mericle AA, McClelland GM, Abram KM. HIV and AIDS risk behaviors in juvenile detainees: implications for public health policy. Am J Public Health. 2003;93:906–12.
Grinstead OA, Faigeles B, Comfort M, Seal DW, Nealey-Moore J, Belcher L, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;4(2):63–80.
Belenko S, Langley S, Crimmins S, Chaple M. HIV risk behaviors, knowledge, and prevention education among offenders under community supervision: a hidden risk group. AIDS Educ Prev. 2004;16:367–85.
MacGowan RJ, Margolis AD, Gaiter J, et al. Predictors of risky sex of young men after release from prison. Int J STD AIDS. 2003;14:519–23.
Morrow KM, Eldridge GD, Nealey-Moore J, Grinstead OA, The Project Start Study Group. HIV, STD, and hepatitis risk in the week following release from prison: an event-level analysis. J Correct Health Care. 2007;13(1):27–38.
Okie S. Sex, drugs, prisons, and HIV. N Engl J Med. 2007;356(2):105–8.
Burattini MN, Massad E, Rozman M, Azevedo RS, Carvalho HB. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000;34(5):431–6.
Mahon N. New York inmates’ HIV risk behaviors: the implications for prevention policy and programs. Am J Public Health. 1996;86:1211–5.
Bryan A, Robbins RN, Ruiz MS, O’Neill D. Effectiveness of an HIV prevention intervention in prison among African Americans, Hispanics, and Caucasians. Health Educ Behav. 2006;33(2):154–77.
Dolan KA, Bijl M, White B. HIV education in a Siberian prison colony for drug dependent males. Int J Equity Health. 2004;3:7.
Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33–41.
Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep. 2005;2(4):165–70.
Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep. 1996;111(Suppl 1):115–22.
Varghese B, Peterman TA. Cost-effectiveness of counseling and testing in US prisons. J Urban Health. 2001;78:304–12.
Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13(13):1745–51.
Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 States - Advancing HIV prevention demonstration project, 2003–2006. Sex Transm Dis. 2009;36(2):S5–8.
Kraut-Becher JR, Gift T, Haddix A, Irwin K, Greifinger R. The cost-effectiveness of universal screening for chlamydia and gonorrhea in United States jails. J Urban Health. 2004;81:453–71.
Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine. 2002;21(3–4):312–21.
Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend. 2006;84(2):160–6.
Wolitski RJ, Project START Writing Group. Relative efficacy of a multisession sexual risk-reduction intervention for young men released from prisons in 4 States. Am J Public Health. 2006;96(10):1854–61.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
Holtgrave DR. Handbook for the economic evaluation of HIV prevention programs. New York: Plenum Press; 1998.
Trentacoste ND, Holtgrave DR, Collins C, Abdul-Quader A. Disseminating effective behavioral interventions for HIV prevention: a cost analysis of a risk-reduction intervention for drug users. J Public Health Manag Pract. 2004;10:130–9.
Grinstead OA, Eldridge G, MacGowan RJ, et al. An HIV, STD, and hepatitis prevention program for young men leaving prison: project START. J Correct Health Care. 2008;14(3):183–96.
Grinstead OA, Seal DW, Wolitski RJ, et al. HIV and STD testing in prisons: perspectives of in-prison service providers. AIDS Educ Prev. 2003;15(6):547–60.
Seal DW, Belcher L, Morrow K, et al. A qualitative study of substance use and sexual behavior among 18- to 29-year-old men while incarcerated in the United States. Health Educ Behav. 2004;3(6):775–89.
Seal DW, Eldridge GD, Kacanek D, Binson D, MacGowan RJ, Project START Study Group. A longitudinal, qualitative analysis of the context of substance use and sexual behavior among 18- to 29-year-old men after their release from prison. Soc Sci Med. 2007;65(11):2394–406.
Seal DW, Margolis AD, Sosman J, Kacanek D, Binson D, Project START Study Group. HIV and STD risk behavior among 18- to 25-year old men released from US prisons: provider perspectives. AIDS Behav. 2003;7(2):131–41.
Seal DW, Margolis AD, Morrow KM, et al. Substance use and sexual behavior during incarceration among 18- to 29-year old men: prevalence and correlates. AIDS Behav. 2008;12:27–40.
Sosman JM, MacGowan RJ, Margolis AD, et al. Screening for sexually transmitted diseases and hepatitis in 18–29-year-old men recently released from prison: feasibility and acceptability. Int J STD AIDS. 2005;16:117–22.
Buck JM, Morrow KM, Margolis A, et al. Hepatitis B vaccination in prison: the perspectives of formerly incarcerated men. J Correct Health Care. 2006;12(1):12–23.
Kacanek D, Eldridge GD, Nealey-Moore J, et al. Young incarcerated men’s perceptions of and experiences with HIV testing. Am J Public Health. 2007;97(7):1209–15.
MacGowan RJ, Eldridge G, Sosman JM, et al. HIV counseling and testing of young men in prison. J Correct Health Care. 2006;12(3):203–13.
Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimate for use in economic evaluation of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(1):54–62.
Hutchison AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43:451–7.
Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2001;15:917–28.
Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–7.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
Acknowledgments
This study was funded through cooperative agreement numbers 414879, 514804, 114812, 914806 by the Centers for Disease Control and Prevention under program announcement number 97050. The authors acknowledge funding from the Canada Research Chairs Program for Ana P. Johnson. The authors thank the study participants and the members of the Project START Study group for their contribution in conducting the study. Project START Study Group members are: John Askew, Lisa Belcher, Gina Best, Jessica Berzowski, Don Bourque, Jeff Buckles, Mark Charles, Achintya N. Dey, Melissa Dispigno, Gloria Eldridge, Christine Fitzgerald, Timothy Flanigan, Marty Fortenberry, Olga Grinstead, Juarlyn Gaiter, Kellie Green, Jacki Hecht, Kashif Iqbal, Brenda Jackson, Ana P. Johnson, Daryl Johnson, Jaclynn Kurpewski, Deborah Kacanek, Carolyn King, Katie Kramer, Melanie Krapf, Annette Lerma, Ricky Lugo, Robin MacGowan, Moribe Lumumba, Kelly Malen, Andrew Margolis, Tim McAuliffe, Kathleen Morrow, Jill Nealey-Moore, Susan Moss, Mobette Nacua, Ann O’Leary, James Sosman, Stephanie Paton, Michael Patterson, Barbara Reed, Ricardo Reed, Merjo Roca, Noel Rosado, David Seal, Rodney Simms, Kimberly Starr, Daniel Strother, Mary Turk, Jerry Vardaman, John M. Williamson, Richard Wolitski, Meghan Woods, Barry Zack.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Johnson, A.P., MacGowan, R.J., Eldridge, G.D. et al. Cost and Threshold Analysis of an HIV/STI/Hepatitis Prevention Intervention for Young Men Leaving Prison: Project START. AIDS Behav 17, 2676–2684 (2013). https://doi.org/10.1007/s10461-011-0096-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-011-0096-7